NCT02862067View on ClinicalTrials.gov

SGLT2 Inhibition in Diabetes and Heart Failure

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions
Diabetes Mellitus, Type 2Heart Failure, Systolic
Interventions
OTHER

Assessment of cardiorespiratory fitness

Assessment of cardiorespiratory fitness

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Virginia Commonwealth University

OTHER

NCT02862067 - SGLT2 Inhibition in Diabetes and Heart Failure | Biotech Hunter | Biotech Hunter